Strategic Initiative

Slingshot members are tracking this corporate initiative:

Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Transaction would add VYXEOS™, an investigational product in development as a treatment for Acute Myeloid Leukemia (AML), to Jazz Pharmaceuticals' portfolio
U.S. regulatory submission for VYXEOS planned by end of third quarter 2016
Jazz Pharmaceuticals to host investor conference call today, May 31, 2016 at 8:30 AM EDT (1:30 PM IST)

  • VYXEOS is the first product candidate to demonstrate a statistically significant improvement in Overall Survival in patients with high-risk (secondary) AML1
  • U.S. FDA Breakthrough Therapy designation granted for VYXEOS2
  • U.S. FDA and European Commission Orphan Drug designation for VYXEOS for the treatment of AML
  • VYXEOS is an innovative product candidate based on the Celator CombiPlex® platform
  • Anticipated long-lived exclusivity for VYXEOS
  • http://investor.jazz...
    Slingshot Insights Explained
    Strategic Initiative Date
    Announcement Date:
    May 31, 2016
    Projected Implementation:
    Q2, 2016
    Relevance Tracked Until:
    Q3, 2016
    Related Projects Image
    • Don’t see a project related to the strategic initiative you care about?

    Related Keywords Vyxeos, Acute Myeloid Leukemia, Aml